Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

951
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
951
Glaucoma: Overview01:25

Glaucoma: Overview

1.2K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.2K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.1K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nanometer scale imaging to develop quantitative descriptors of bipolar membrane junction structure.

Scientific reports·2026
Same author

Ion Transport in Charged Membranes: Linking Electric-Field-Driven Mechanisms to Pore Size via Perturbation Analysis.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Relapse in patients with non-ischemic dilated cardiomyopathy and improved ejection fraction managed with medical therapy.

Indian heart journal·2026
Same author

A privacy preserving optimized intelligent security framework for smart homes using zero trust architecture and explainability.

Scientific reports·2026
Same author

Spatially Mapping the CO<sub>2</sub> Alkaline Sorbent Diffuse Microenvironment Using Operando Raman Spectroscopy.

ACS energy letters·2026
Same author

High-fat diet causes rapid loss of intestinal group 3 innate lymphoid cells through microbiota-driven inflammation and mitochondrial stress.

Immunity·2026

Related Experiment Video

Updated: Jan 12, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K

Leptin as a neuroprotective agent in glaucoma.

Ankur Gupta1

  • 1Royal Derby Hospital, Uttoxeter Road, Derby, UK.

Medical Hypotheses
|September 17, 2013
PubMed
Summary

Leptin shows promise as a novel neuroprotective agent for glaucoma, a leading cause of irreversible blindness. This approach targets retinal ganglion cell death, addressing the disease

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Endocrinology

Background:

  • Glaucoma is a leading cause of irreversible blindness, affecting over 60 million people globally.
  • Current treatments focus on reducing intraocular pressure but do not address the underlying retinal ganglion cell degeneration.
  • Glaucomatous neurodegeneration shares similarities with other central nervous system neurodegenerative diseases.

Purpose of the Study:

  • To explore leptin as a potential neuroprotective agent for glaucoma management.
  • To investigate leptin's mechanisms of action in protecting retinal ganglion cells.

Main Methods:

  • Review of existing literature on leptin's neuroprotective effects in neurodegenerative diseases.
  • Analysis of molecular mechanisms underlying glaucoma, including apoptosis, oxidative stress, and excitotoxicity.

More Related Videos

Morphometric Analyses of Retinal Sections
14:33

Morphometric Analyses of Retinal Sections

Published on: February 19, 2012

10.7K
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 3, 2007

11.7K

Related Experiment Videos

Last Updated: Jan 12, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

13.5K
Morphometric Analyses of Retinal Sections
14:33

Morphometric Analyses of Retinal Sections

Published on: February 19, 2012

10.7K
Laser-Induced Chronic Ocular Hypertension Model on SD Rats
06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 3, 2007

11.7K
  • Correlation of leptin's known functions with pathways implicated in glaucomatous optic neuropathy.

    • Main Results:

    • Leptin has demonstrated neuroprotective capabilities in various neurodegenerative conditions.
    • Evidence suggests glaucomatous neurodegeneration involves pathways that leptin can modulate.
    • Potential mechanisms include reduction of apoptosis, oxidative stress, and excitotoxicity in retinal ganglion cells.

    Conclusions:

    • Leptin presents a promising therapeutic avenue for glaucoma by targeting its underlying pathology.
    • A neuroprotective strategy using leptin could offer broader clinical benefits than current intraocular pressure-lowering treatments.
    • Further research is warranted to validate leptin's efficacy and safety in glaucoma management.